Wird geladen...
Lenalidomide decreased the PSA level for castration‐resistant prostate cancer: a case report
Lenalidomide has been developed as the derivative of thalidomide that has fewer side effects. We herein report a rare case of castration‐resistant prostate cancer successfully maintained using lenalidomide for multiple myeloma.
Gespeichert in:
| Veröffentlicht in: | Clin Case Rep |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
John Wiley and Sons Inc.
2018
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5799614/ https://ncbi.nlm.nih.gov/pubmed/29445483 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ccr3.1328 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|